Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients

(2019) Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatry.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: This study determined the effects of a novel combination of vitamin D and probiotic on metabolic and clinical symptoms in chronic schizophrenia. Methods: This trial was conducted among 60 patients with chronic schizophrenia to receive either 50,000 IU vitamin D3 every 2 weeks plus 8 × 10 9 CFU/day probiotic (n = 30) or placebo (n = 30) for 12 weeks. Results: Vitamin D and probiotic co-supplementation was associated with a significant improvement in the general (- 3.1 ± 4.7 vs. + 0.3 ± 3.9, P = 0.004) and total PANSS scores (- 7.4 ± 8.7 vs. -1.9 ± 7.5, P = 0.01). Vitamin D and probiotic co-supplementation also significantly increased total antioxidant capacity (+ 51.1 ± 129.7 vs. -20.7 ± 53.3 mmol/L, P = 0.007), and significantly decreased malondialdehyde (- 0.3 ± 0.9 vs. + 0.2 ± 0.4 μmol/L, P = 0.01) and high sensitivity C-reactive protein levels (- 2.3 ± 3.0 vs. -0.3 ± 0.8 mg/L, P = 0.001) compared with the placebo. Moreover, taking vitamin D plus probiotic significantly reduced fasting plasma glucose (- 7.0 ± 9.9 vs. -0.2 ± 9.9 mg/dL, P = 0.01), insulin concentrations (- 2.7 ± 2.3 vs. + 0.4 ± 2.0 μIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (- 0.8 ± 0.7 vs. + 0.1 ± 0.7, P < 0.001), triglycerides (- 7.8 ± 25.2 vs. + 10.1 ± 30.8 mg/dL, P = 0.01) and total cholesterol levels (- 4.9 ± 15.0 vs. + 5.9 ± 19.5 mg/dL, P = 0.04) and total-/HDL-cholesterol ratio (- 0.1 ± 0.6 vs. + 0.3 ± 0.8, P = 0.04). Conclusion: Probiotic and vitamin D for 12 weeks to chronic schizophrenia had beneficial effects on the general and total PANSS score, and metabolic profiles. Trial Registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical trials registration (http://www.irct.ir: IRCT2017072333551N2). 07-31-2017 2 © 2019 The Author(s).

Item Type: Article
Keywords: C reactive protein; cholesterol; colecalciferol; glucose; high density lipoprotein cholesterol; insulin; lactocare; malonaldehyde; placebo; probiotic agent; triacylglycerol; antioxidant; malonaldehyde; probiotic agent; vitamin; vitamin D, adult; Article; controlled study; double blind procedure; fasting; female; glucose blood level; homeostasis model assessment; human; major clinical study; male; metabolism; Positive and Negative Syndrome Scale; randomized controlled trial; schizophrenia; supplementation; blood; dietary supplement; insulin resistance; Iran; middle aged; schizophrenia, Adult; Antioxidants; Dietary Supplements; Double-Blind Method; Female; Humans; Insulin Resistance; Iran; Male; Malondialdehyde; Middle Aged; Probiotics; Schizophrenia; Vitamin D; Vitamins
Journal or Publication Title: BMC Psychiatry
Volume: 19
Number: 1
Identification Number: 10.1186/s12888-019-2059-x
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/2089

Actions (login required)

View Item View Item